ASCO Preview: Three Chinese Biotechs To Watch
Executive Summary
BeiGene, Ascentage Pharma and I-Mab will be among the first Chinese pharma firms to report clinical trial results for their innovative drug candidates at this year’s ASCO meeting.
You may also be interested in...
China Planning To Ban Gene Editing Technology Exports
Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.
Chinese Balloon Affair To Blow Up US Health Collaboration?
The latest surveillance balloon downing could torpedo improving bilateral health collaboration between China and the US at a time when warming ties are crucial to solving a flurry of gridlocks.
Chinese Balloon Affair To Blow Up US Health Collaboration?
The latest surveillance balloon downing could torpedo improving bilateral health collaboration between China and the US at a time when warming ties are crucial to solving a flurry of gridlocks.